Preclinical pharmacokinetics-pharmacodynamics (PK-PD) modeling of TAK-733, an investigational MEK inhibitor

被引：0
|
作者：
Le, K. [1 ]
Chakravarty, A. [2 ]
Walker, R. [3 ]
Izmailova, E. [3 ]
Vincent, P. [4 ]
O'Connell, S. [4 ]
Prakash, S. [1 ]
机构：
[1] Millennium Takeda Oncol Co, Drug Metab & Pharmacokinet, Cambridge, MA USA
[2] Millennium Takeda Oncol Co, Canc Pharmacol, Cambridge, MA USA
[3] Millennium Takeda Oncol Co, Mol Med, Cambridge, MA USA
[4] Takeda San Diego Inc, Discovery Biol, San Diego, CA USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72307-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：188 / 189
页数：2
相关论文
共 50 条
  • [41] Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831, a Selective D-amino Acid Oxiciase Inhibitor, in Healthy Volunteers
    Xu, Lin
    DeMartinis, Nicholas
    Wu, Jingtao
    Asgharnejad, Mahnaz
    Quinton, Maria S.
    Wendland, Jens R.
    O'Donnell, Patricio
    NEUROLOGY, 2019, 92 (15)
  • [42] SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF SINGLE DOSES OF TAK-272, A NOVEL RENIN INHIBITOR, IN HEALTHY MALE SUBJECTS
    Matsuno, K.
    Kuroda, S.
    Tanaka, S.
    Nakamichi, H.
    Komura, E.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [43] Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients.
    Menon, SS
    Whitfield, LR
    Sadis, S
    Meyer, MB
    Leopold, J
    Lorusso, PM
    Krishnamurthi, S
    Rinehart, JR
    Nabell, L
    Croghan, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [44] Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research
    Poulin, Patrick
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (06) : 2110 - 2118
  • [45] PHASE I AND PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) STUDY OF MEK INHIBITOR, RO4987655, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nakamichi, S.
    Nokihara, H.
    Yamamoto, N.
    Tamura, Y.
    Honda, K.
    Wakui, H.
    Yamada, Y.
    Yamazaki, N.
    Suzuki, S.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 156 - 156
  • [46] Effect of SRD5A2 genotype on pharmacodynamics of 5-alpha-reductase inhibitor analyzed by PK-PD modeling.
    Chung, J
    Cho, J
    Lim, H
    Oh, D
    Yi, S
    Jang, I
    Shin, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P12 - P12
  • [47] PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EXPOSURE-PD RELATIONSHIPS OF THE INVESTIGATIONAL DRUG MLN8237, AN AURORA A KINASE INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Zhou, X.
    Ecsedy, J.
    Danaee, H.
    Fingert, H.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S67 - S67
  • [48] Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
    Yamada, Yasuhide
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Fujiwara, Yutaka
    Tamura, Yosuke
    Wakui, Hiroshi
    Honda, Kazunori
    Nakamichi, Shinji
    Asahina, Hajime
    Tanabe, Yuko
    Kitazono, Satoru
    Mizugaki, Hidenori
    Yamazaki, Naoya
    Suzuki, Shigenobu
    Sasaki, Junichi
    Matsuoka, Mieko
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] Influence of release rate, dose and co-administration on pharmacokinetics, pharmacodynamics and PK-PD relationship of tanshinone IIA and tanshinol
    Li, Zhenghua
    Li, Ziyi
    Wang, Bingwei
    Liu, Jianping
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 168
  • [50] Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using 18F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549
    Seigo Ishino
    Hiroshi Miyake
    Patrick Vincent
    Ikuo Mori
    Annals of Nuclear Medicine, 2015, 29 : 613 - 620
12345